#METiS TechBio #Boulevard Bio #trispecific T-cell

Partnership Announcement: METiS TechBio and Boulevard Bio

In a landmark development within the pharmaceutical industry, METiS TechBio, an innovative company specializing in AI-driven drug delivery, has forged an exclusive global licensing agreement with Boulevard Bio, a renowned U.S. biotechnology firm funded by Deerfield Management. This partnership grants Boulevard worldwide rights to develop, manufacture, and commercialize the novel trispecific T-cell engager (TCE) program, known as MTS-128, which was originally created by METiS TechBio.

Details of the Agreement

As part of the agreement, METiS TechBio will receive an upfront payment of $20 million and stands to gain up to a staggering $1.6 billion in various developmental, regulatory, and commercialization milestone payments. Furthermore, they will also benefit from tiered royalties linked to product sales. This financial structure reflects the potential value and market viability of the MTS-128 program, indicating confidence in its future success.

Innovative Technology Behind MTS-128

MTS-128 is a pioneering trispecific T-cell engager, developed through the groundbreaking NanoForge platform utilized by METiS TechBio. This AI-powered platform integrates cutting-edge technology across protein design, drug delivery system engineering, and therapeutic innovation, showcasing the company's capability to advance drug discovery through technology. Unlike traditional antibody discovery practices that often rely on trial and error, MTS-128 has been engineered from the ground up using precise AI-driven molecular engineering. This innovative approach significantly enhances the therapeutic potential of T-cell engagers.

Trispecific TCEs such as MTS-128 can engage with multiple biological mechanisms simultaneously, enhancing the efficiency of targeting and killing cancer cells while minimizing off-target toxicity. This technological advancement signifies a substantial leap forward compared to conventional bispecific T-cell engagers, which are limited in their engagement capabilities.

A Broader Vision for Drug Delivery Innovation

The partnership represents more than just a licensing agreement; it is a unique step forward in the realm of drug delivery technology. Chris Lai, Chairman and CEO of METiS TechBio, asserts that this collaboration is pivotal for AI-driven drug delivery innovations, especially in China. He emphasizes that the MTS-128 program stands as a testament to the potential of the NanoForge platform, facilitating next-generation drug discovery. Furthermore, METiS TechBio aims to leverage this groundbreaking technology to deliver accessible and innovative treatments to patients across the globe.

The revolutionary NanoForge platform is engineered around a holistic framework that merges computational